In delivering software, we often face a choice: adopt an all-in-one solution with features we’ll never use, or cobble together multiple systems that don’t talk to each other properly. At Mayet, we decided it’s time for a different approach. We Asked, You Answered Since launching Mayet, we’ve had hundreds of conversations with clients and prospects…

We’re excited to announce our first integration partnership that connects our Vendor Management Software (VMS) with, PHARMASEAL, leading Clinical Trial Management System (CTMS). This powerful combination addresses key challenges faced by clinical research organisations today. See press release HERE: A Game-Changing Integration Our integration of Mayet and PHARMASEAL gives clinical trial teams complete visibility across…

We are delighted to announce the appointment of Rosemarie Corrigan as Strategic Advisor to Mayet. With over three decades of experience in clinical research and medicines development, Rosemarie brings invaluable quality assurance and regulatory expertise to support Mayet’s growth trajectory. Rosemarie on joining Mayet: “Mayet’s platform transforms vendor oversight in life sciences, combining quality expertise…

The updates to ICH E6(R3) reflect the increasing complexity of clinical trials by establishing more explicit requirements for service provider management. While sponsors and investigators have always been accountable for trial activities, the new guidelines provide clearer expectations for vendor oversight in an ecosystem increasingly dependent on specialised service providers. Understanding these requirements is essential…

Why People Matter More Than Ever In the rush to adopt new technologies and adapt to regulatory changes, it’s easy to lose sight of what truly drives clinical trial quality: people. At RQA 2024, the most impactful moment wasn’t a technical presentation or regulatory update – it was a patient advocate sharing their journey, reminding…

We are delighted to announce the appointment of Dr. Andrew Copestake as Strategic Advisor to Mayet. With over three decades of executive leadership experience in the pharmaceutical, biotechnology, and CRO sectors, Dr. Copestake brings invaluable commercial and strategic expertise to support Mayet’s growth trajectory. Dr. Copestake on joining Mayet: “Mayet is a unique and sophisticated…

The Evolution of Service Provider Relationships The clinical trial landscape has fundamentally changed. As highlighted at recent industry conferences, including RQA 2024 and COG Europe, the terminology shift in ICH E6(R3) from “CRO” to “service provider” (mentioned 36 times compared to the previous 9) signals more than a simple language update – it represents a…

The Quality Landscape Is Shifting If you’re a quality professional in clinical research, you’ve likely noticed how rapidly the landscape is changing. Between artificial intelligence applications, decentralised trials, and evolving regulatory frameworks, it can feel like you’re constantly playing catch-up. You’re not alone – at recent industry conferences like RQA 2024 and COG Europe, these…

This Blog Post Series – Summarising Recent Conference Themes Over the past few months, I’ve had the privilege of participating in several key industry events, including RQA 2024 in Brighton and COG Europe in Amsterdam. Through presentations, panel discussions, and countless conversations with industry colleagues, several crucial themes have emerged that I believe warrant deeper…

In September 2024, the FDA finalised its guidance on conducting decentralized clinical trials (DCTs) and integrating decentralized elements into traditional trial models. This new guidance aims to address evolving practices in clinical trials that leverage remote methods, digital health technologies (DHTs), and decentralized service providers. The primary goal? To make trials more accessible, efficient, and…